NCT05788016

Brief Summary

The goal of this clinical trial is to develop an pharmacist-led preoperative opioid taper intervention for patients undergoing total knee or hip replacement who are on chronic opioids before their surgery. The main questions it aims to answer are:

  • Is the intervention feasible and acceptable to patients?
  • Does the intervention result in a decrease in opioid dose during the preoperative period? Participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
45

participants targeted

Target at P25-P50 for not_applicable

Timeline
11mo left

Started Jan 2024

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress74%
Jan 2024Jul 2027

First Submitted

Initial submission to the registry

March 2, 2023

Completed
26 days until next milestone

First Posted

Study publicly available on registry

March 28, 2023

Completed
10 months until next milestone

Study Start

First participant enrolled

January 10, 2024

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2026

Expected
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2027

Last Updated

May 29, 2026

Status Verified

May 1, 2026

Enrollment Period

2.7 years

First QC Date

March 2, 2023

Last Update Submit

May 27, 2026

Conditions

Keywords

Opioids

Outcome Measures

Primary Outcomes (1)

  • Acceptability

    Mixed-methods assessment of the intervention by participants. Participants will provide qualitative feedback at multiple points during and after the intervention, and will quantitatively rate satisfaction at the end of the study. These results will be analyzed jointly to determine acceptability.

    From enrollment until approximately 2 weeks after surgery

Secondary Outcomes (4)

  • Study Recruitment Rate

    From enrollment until approximately 2 weeks after surgery

  • Study Retention Rate

    From enrollment until approximately 2 weeks after surgery

  • Taper Efficacy

    From enrollment until the time of surgery

  • Perioperative Pain

    From enrollment until approximately 2 weeks after surgery

Study Arms (1)

Pharmacist-led opioid taper intervention

EXPERIMENTAL

The participant will attempt to taper their opioid dose by \~50% during the 4-6 week preoperative period. Participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.

Behavioral: opioid taper

Interventions

opioid taperBEHAVIORAL

The participant will attempt to taper their opioid dose by \~50% during the 4-6 week preoperative period

Pharmacist-led opioid taper intervention

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • decided to pursue primary, unilateral total knee or hip arthroplasty with planned surgery date in 4-8 weeks
  • currently taking between 20 and 90 MME of oral opioids, and that dose has been stable for at least 3 months
  • have a reliable telephone number for contact
  • speaks English

You may not qualify if:

  • Taking opioid medications that include:
  • Buprenorphine
  • Methadone
  • Long-acting formulations of opioid pain medications (e.g., extended-release oxycodone and extended-release morphine)
  • Transdermal formations of opioid pain medications (e.g., fentanyl patches)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UAB Hospital-Highlands

Birmingham, Alabama, 35205, United States

RECRUITING

MeSH Terms

Conditions

Chronic Pain

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Kevin R Riggs, MD

    University of Alabama at Birmingham

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Kevin R Riggs, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

March 2, 2023

First Posted

March 28, 2023

Study Start

January 10, 2024

Primary Completion (Estimated)

October 1, 2026

Study Completion (Estimated)

July 1, 2027

Last Updated

May 29, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

Locations